These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35081851)

  • 1. Advances in the drug management of basal cell carcinoma.
    Ramelyte E; Restivo G; Mannino M; Levesque MP; Dummer R
    Expert Opin Pharmacother; 2022 Apr; 23(5):573-582. PubMed ID: 35081851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation.
    Villani A; Scalvenzi M; Micali G; Lacarrubba F; Genco L; Ruggiero A; Fornaro L; Guerrasio G; Potestio L
    Expert Opin Drug Saf; 2023; 22(7):525-531. PubMed ID: 37326221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current clinical approach to difficult-to-treat basal cell carcinomas.
    Di Brizzi EV; Argenziano G; Brancaccio G; Scharf C; Ronchi A; Moscarella E
    Expert Rev Anticancer Ther; 2023 Jan; 23(1):43-56. PubMed ID: 36579630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic treatment options for advanced epithelial skin cancer.
    Soura E; Chasapi V; Stratigos AJ
    Expert Opin Pharmacother; 2015; 16(10):1479-93. PubMed ID: 26027692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits.
    Villani A; Cinelli E; Fabbrocini G; Lallas A; Scalvenzi M
    Expert Opin Drug Saf; 2020 Dec; 19(12):1585-1594. PubMed ID: 33054455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Hedgehog pathway and its inhibitors: Emerging therapeutic approaches for basal cell carcinoma.
    Jain R; Dubey SK; Singhvi G
    Drug Discov Today; 2022 Apr; 27(4):1176-1183. PubMed ID: 34896624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging drugs for the treatment of basal cell carcinoma.
    Herms F; Basset-Seguin N
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):17-26. PubMed ID: 33412913
    [No Abstract]   [Full Text] [Related]  

  • 8. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.
    Peris K; Fargnoli MC; Garbe C; Kaufmann R; Bastholt L; Seguin NB; Bataille V; Marmol VD; Dummer R; Harwood CA; Hauschild A; Höller C; Haedersdal M; Malvehy J; Middleton MR; Morton CA; Nagore E; Stratigos AJ; Szeimies RM; Tagliaferri L; Trakatelli M; Zalaudek I; Eggermont A; Grob JJ;
    Eur J Cancer; 2019 Sep; 118():10-34. PubMed ID: 31288208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
    Leavitt E; Lask G; Martin S
    Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on the current and emerging pharmacotherapies for basal cell carcinomas.
    Villani A; Scalvenzi M; Micali G; Martora F; Cillo F; Raia F; Potestio L
    Expert Opin Pharmacother; 2023; 24(18):2143-2151. PubMed ID: 37963910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical hedgehog inhibitors for basal cell carcinoma: how far away are we?
    Zhu H; Lewis DJ
    Expert Opin Pharmacother; 2022 Apr; 23(6):739-740. PubMed ID: 35258366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Swiss Recommendations for Cutaneous Basal Cell Carcinoma.
    Ramelyte E; Nägeli MC; Hunger R; Merat R; Gaide O; Navarini AA; Cozzio A; Wagner NB; Maul LV; Dummer R
    Dermatology; 2023; 239(1):122-131. PubMed ID: 36137524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the treatment of Basal cell carcinoma: Hedgehog inhibitors.
    Kudchadkar R; Lewis K; Gonzalez R
    Semin Oncol; 2012 Apr; 39(2):139-44. PubMed ID: 22484185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.
    Love WE; Bernhard JD; Bordeaux JS
    Arch Dermatol; 2009 Dec; 145(12):1431-8. PubMed ID: 20026854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.
    Lyons TG; O'Kane GM; Kelly CM
    Expert Opin Drug Saf; 2014 Aug; 13(8):1125-32. PubMed ID: 25033383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging trends in the treatment of advanced basal cell carcinoma.
    Migden MR; Chang ALS; Dirix L; Stratigos AJ; Lear JT
    Cancer Treat Rev; 2018 Mar; 64():1-10. PubMed ID: 29407368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
    Rudnick EW; Thareja S; Cherpelis B
    Int J Dermatol; 2016 Mar; 55(3):249-58; quiz 256, 258. PubMed ID: 26566923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging drugs and combination strategies for basal cell carcinoma.
    Dreier J; Dummer R; Felderer L; Nägeli M; Gobbi S; Kunstfeld R
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):353-65. PubMed ID: 24773312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.